Chromosomal markers in lymphoma diagnosis

Current Diagnostic Pathology

Volumn 3, Issue 4, 1996, Pages 187-199

  Kluin, M Ph ^a   Vaandrager, J W ^a   Van Krieken, J H J M ^a   Schuuring, E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343757051     PISSN: 09686053     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0968-6053(96)80001-9     Document Type: Article

References (155)

1. Banks P M, Chan J, Cleary M L et al. Mantle cell lymphoma: a proposai for unification of morphologie, immunologie, and molecular data. Am J Surg Pathol 1992; 16: 637-640.
2. Shivdasani R A, Hess J L, Skarin A T, Pinkus G S. Intermediate lymphocytic lymphoma: clinical and pathologie features of a recently characterized subtype of non-Hodgkin's lymphoma. JClinOncol 1993; 11:802-811.
3. Zucca E, Stein H, Coiffier B. European lymphoma task force (ELTF): report of the workshop on mantle cell lymphoma (MCL). Ann Oncol 1994; 5: 507-511.
4. Velders G A, KIuin-Nelemans J C, De Boer C J et al. Mantle cell lymphoma: a population based clinical study. J Clin Oncol 1996; 14: 1269-1274.
5. Lennert K. Malignant lymphoma other than Hodgkin's disease. Springer Semin Immunopathol 1978.
6. Duggan M J, Weisenburger D D, Ye Y L et al. Mantle zone lymphoma: a clinicopathologic study of 22 cases. Cancer 1990; 66:522-529.
7. Weisenburger D D, Sanger W G, Armitage J O, Purtilo D T. Intermediate lymphocytic lymphoma: immunophenotypic and cytogenetic findings. Blood 1987; 69: 1617-1621.
8. Weisenburger D D, Kim H, Rappaport H. Mantle zone lymphoma. A follicular variant of intermediate lymphocytic lymphoma. Cancer 1982; 49: 1429-1438.
9. Palutke M, Eisenberg L, Mirchandani I, Tabaczka P, Husain M. Malignant lymphoma of small cleaved lymphocytes of the follicular mantle zone. Blood 1982; 59: 317-322.
10. Nanba K, Jaffe E S, Braylan R C, Soban E J, Berard C W. Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas. Am J Clin Pathol 1977; 68: 535-542.
11. The Non-Hodgkin's lymphoma pathologic classification project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas. Summary and description of a working formulation for clinical use. Cancer 1982; 49:2112-2135.
12. Harris N L, Jaffe E S, Stein H et al. A revised EuropeanAmerican classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
13. Garcia-Conde J, Cabanillas F. Mantle cell lymphoma: a lymphoproliferative disorder with aberrant function of the cell cycle. Leukemia 1996; 10: S78-S83.
14. Louie D C, Offit K, Jaslow R et al. P53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(ll;14)(ql3;q32). Blood 1995; 86: 2892-2899.
15. Koduru P R K, Zariwala M, Soni M, Gong J Z, Xiong Y, Broome J D. Deletion of cyclin dependent kinase 4 inhibitor genes p!5 and p!6 in Non-Hodgkin's Lymphoma. Blood 1995; 86:2900-2905.
16. Hemandez L, Fest T, Cazorla M et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphoma. Blood 1996; 87: 3351-3359.
17. Greiner T C, Moynihan M J, Chan W C et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996; 87:4302-4310.
18. Loyson S A J, De Boer C J, Schuuring E, Kluin P M, Van Krieken J H J M. Mantle cell lymphoma. A morphological, immunohistochemical and molecular genetic study. Path Res Pract 1996; 192: 1-11.
19. Segal G H, Masih A S, Fox A C, Jorgensen T, Scott M, Braylan R C. CDS-expressing B-cell Non-Hodgkin's Lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995; 85: 157CM579.
20. Ott M M, Ott G, Kuse R et al. The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices. Histopathology 1994; 24: 329-334.
21. Louie D C, Offit K, Jaslow R et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(ll;14)(ql3;q32). Blood 1995; 86: 2892-2899.
22. Vandenberghe E, De Wolf-Peelers C, Van den Oord J et al. Translocation (11; 14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. J Pathol 1991; 163: 13-18.
23. Pittaluga S, Verhoef G, Criel A et al. "Small" B-cell nonHodgkin's lymphomas with splenomegaly at presentation are either mantle cell lymphoma or marginal zone cell lymphoma. A study based on histology, cytology, immunohistochemistry, and cytogenetic analysis. Am J Surg Pathol 1996; 20: 211-223.
24. Daniel M T, Tigaud I, Flexor M A, Nogueira M E, Berger R, Jonveaux P. Leukaemic non-Hodgkin's lymphomas with hyperdiploid cells and t(l I;14)(ql3;q32): a subtype of mantle cell lymphoma? Br J Haematol 1995; 90: 77-84.
25. Leroux D, Le Marc'Hadour F, Gressin R et al. Non-Hodgkin's lymphomas with t(l I;14)(ql3;q32): a subset of mantle zone/intermediate lymphocytic lymphoma. Br J Haematol 1991; 77: 346-353.
26. De Boer C J, Van Krieken J H J M, Schuuring E, Kluin P M. BCLl/cyclin Dl in malignant lymphoma. Ann Oncol 1996; in press:
27. Cuneo A, Balboni M, Piva N et al. Atypical chronic lymphocytic leukaemia with t(l I;14)(ql3;q32): karyotype evolution and prolymphocytic transformation. Br J Haematol 1995; 90:409-416.
28. Gaidano G, Newcomb E W, Gong J Z et al. Analysis of alterations of oncogenes and tumor suppressor genes in chronic lymphocytic leukemia. Am J Pathol 1994; 144: 1312-1319.
29. Bird M L, Ueshima Y, Rowley J D, Hären J M, Vardiman J W. Chromosome abnormalities in B cell chronic lymphocytic leukemia and their clinical correlations. Leukemia 1989; 3: 182-191.
30. Juliusson G, Oscier D G, Fitchett M et al. Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med 1990; 323: 720-724.
31. Jadayel D, Matutes E, Dyer M J S et al. Splenic lymphoma with villous lymphocytes: analysis of BCL-1 rearrangements and expression of the cyclin Dl gene. Blood 1994; 83: 3664-3671.
32. Oscier D G, Matutes E, Gardiner A et al. Cytogenetic studies in splenic lymphoma with villous lymphocytes. Br J Haematol 1993; 85:48791.
33. VandenBerghe H, Vermaelen K, Louwagie A, Criel A, Mecucci C, Vaerman J-P. High incidence of chromosome abnormalities in IgG3 myeloma. Cancer Genet Cytogenet 1984; 11: 381-387.
34. Weh H J, Gutensohn K, Seibach J et al. Karyotype in multiple myeloma and plasma cell leukaemia. Eur J Cancer [A] 1993; 29A: 1269-1273.
35. Kubonishi I, Seto M, Shimamura T, Enzan H, Miyoshi I. The establishment of an interleukin-6-dependent myeloma cell line (FLAM-76) carrying t(ll;14)(ql3;q32) chromosome abnormality from an aggressive nonsecretory plasma cell leukemia. Cancer 1992; 70: 1528-1535.
36. Nishida K, Taniwaki M, Misawa S, Abe T. Nonrandom rearrangement of chromosome 14 at band q32.33 in human lymphoid malignancies with mature B-cell phenotype. Cancer Res 1989; 49: 1275-1281.
37. Fiedler W, Weh H J, Hossfeld D K. Comparison of chromosome analysis and BCL-1 rearrangement in a series of patients with multiple myeloma. Br J Haematol 1992; 81:58-61.
38. Heim S, Mitelman F. Cancer Cytogenetics, 2nd ed. New York: Wiley-Liss, 1995.
39. Juliusson G, Friberg K, Gahrton G. Consistency of chromosomal aberrations in chronic B-lymphocytic leukemia; a longitudinal cytogenetic study of 41 patients. Cancer 1988; 62:500-506.
40. Tsujimoto Y, Yunis J J, Onorato-Showe L, Erikson J, Nowell P C, Croce C M. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(ll;14) chromosome translocation. Science 1984; 224: 1403-1406.
41. Tsujimoto Y, Jaffe E, Cossman J, Gorham J, Nowell P, Croce C M. Clustering of breakpoints on chromosome 11 in human B-cell neoplasms with the t(l 1;14) chromosome translocation. Nature 1985; 315: 340-343.
42. Galiegue-Zouitina S, Collyn-d'Hooge M, Denis C et al. Molecular cloning of a t(l I;14)(ql3;q32) translocation breakpoint centromeric to the BCL1-MTC. Genes Chromosom Cancer 1994; 11:246-255.
43. Williams M E, Meeker T C, Swerdlow S H. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. Blood 1991; 78:493-498.
44. Rosenberg C L, Wong E, Petty E M et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sei USA 1991; 88: 9638-9642.
45. De Boer C J, Loyson S, Kluin P M, Kluin-Nelemans J C, Schuuring E, Van Krieken J H J M. Multiple breakpoints within the BCL-1 locus in B-cell lymphoma: rearrangements of the cyclin Dl gene. Cancer Res 1993; 53:4148-4152.
46. Raynaud S D, Gratecos N, Simon M P et al. Fluorescent in situ hybridization analysis of an atypical t(l I;14)(ql3;q32) without expression of the cyclin Dl gene. Leukemia 1993; 7: 1924-1927.
47. Williams M E, Swerdlow S H, Rosenberg C L, Arnold A. Chromosome 11 translocation breakpoints at the PRADl/cyclin Dl gene locus in centrocytic lymphoma. Leukemia 1993; 7:241-245.
48. De Boer C J, Schuuring E, Dreef E J et al. Cyclin Dl protein analysis in the diagnosis of mantle cell lymphonia. Blood 1995; 86:2715-2723.
49. Chesi M, Bergsagel P L, Brents L A, Smith C M, Gerhard D S, Kuehl WM. Dysregulation of cyclin Dl by translocation into IgH gamma switch region in two multiple myeloma cell lines. Blood 1996; 88: 674-681.
50. Williams M E, Swerdlow S H, Meeker T C. Chromosome t(ll;14)(q3;q32) breakpoints are highly localized at the BCL-1 major translocation cluster. Leukemia 1993; 7: 1437-1440.
51. Rimokh R, Berger F, Delsol G et al. Detection of the chromosomal translocation t(ll;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994; 83: 1871-1875.
52. Luthra R, Hai S, Pugh W C. Polymerase chain reaction detection of the t(l 1;14) translocation involving the bcl-1 major translocation cluster in mantle cell lymphoma. Diagn Mol Pathol 1995; 4:4-7.
53. Raynaud S D, Bekri S, Leroux D et al. Expanded range of l Iql3 breakpoints with differing patterns of cyclin Dl expression in B-cell malignancies. Gen Chrom Cane 1993; 8: 80-87.
54. Zucca E, Soldat! G, Schlegelberger B et al. Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma. Br J Haematol 1995; 89:665-668.
55. Bigoni R, Negrini M, Veronese M L, Cuneo A, Castoldi G L, Croce CM. Characterization of t(ll;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 1996; 13:797-802.
56. Coignet L J A, Schuuring E, Kibbelaar R E et al. Detection of 1 Iql3 rearrangements in hématologie neoplasias by double color fluorescence in situ hybridization. Blood 1996; 87: 1512-1519.
57. Vaandrager J W, Schuuring E, Zwikstra E et al. Direct visualization of dispersed 1 Iql3 chromosomal translocations in mantle cell lymphoma by multi-color DNA fiber FISH. Blood 1996; 88: 1177-1182.
58. Wiegant J, Kalle W, Mullenders L et al. High-resolution in situ hybridization using DNA halo preparations. Hum Mol Genet 1992; 1:587-591.
59. Florijn R J, Blonden L A J, Vrolijk H et al. High-resolution DNA Fiber-FISH for genomic DNA mapping and colour bar-coding of large genes. Hum Mol Genet 1995; 4: 831-836.
60. Heiskanen M, Hellsten E, Kallioniemi O-P et al. Visual mapping by fiber FISH. Genomics 1995; 30: 31-36.
61. Fidlerova H, Senger G, Kost M, Sanseau P, Sheer D. Two simple procedures for releasing chromatin from routinely fixed cells for fluorescence in situ hybridisation. Cytogenet Cell Genet 1994; 65: 203-205.
62. Heiskanen M, Karhu R, Hellsten E, Peltonen L, Kallioniemi O-P, Palotie A. High resolution mapping using Fluorescence In Situ Hybridization to extended DNA fibers prepared from agarose-embedded cells. BioTechniques 1994; 17: 928-933.
63. Parra I, Windle B. High resolution visual mapping of stretched DNA by fluorescent hybridization. Nature Genet 1993; 5: 17-21.
64. Heng H H Q, Squire J, Tsui L-C. High-resolution mapping of mammalian genes by in 51/11 hybridization to free chromatin. Proc Natl Acad Sei USA 1992; 89: 9509-9513.
65. De Boer C J, Kluin-Nelemans J C, Dreef E J et al. Involvement of the CCND1 gene in hairy cell leukemia. Ann Oncol 1996; 7:251-256.
66. Bosch F, Campo E, Jares P et al. Increased expression of the PRAD-1/CCND1 gene in hairy cell leukemia. Br J Haematol 1995; 91: 1025-1030.
67. De Boer C J, Van Krieken J H J M, Kluin-Nelemans J C, Kluin P M, Schuuring E. Cyclin Dl messenger RNA overexpression as a marker for mantle cell lymphoma. Oncogene 1995; 10: 1833-1840.
68. Swerdlow S H, Yang W I, Zukerberg L R, Harris N L, Arnold A, Williams M E. Expression of cyclin Dl protein in centrocytic/mantle cell lymphomas with and without rearrangement of the BCLl/cyclin Dl gene. Hum Pathol 1995; 26: 999-1004.
69. Zukerberg L R, Yang W I, Arnold A, Harris N L. Cyclin Dl expression in non-Hodgkin's lymphomas. Detection by immunohistochemistry. Am J Clin Pathol 1995; 103: 756-760.
70. Yang W I, Zukerberg L R, Motokura T, Arnold A, Harris N L. Cyclin Dl (Bcl-1, Pradl) protein expression in low grade B-cell lymphomas and reactive hyperplasia. Am J Pathol 1994; 145: 86-96.
71. Rimokh R, Berger F, Bastard C et al. Rearrangement of CCND1 (BCL1/PRAD1) y untranslated region in mantle cell lymphomas and t(llql3)-associated leukemias. Blood 1994; 83: 3689-3696.
72. Fukuhara S, Rowley J D, Variakojis D, Colomb H M. Chromosome abnormalities in poorly differentiated lymphocytic lymphoma. Cancer Res 1979; 39: 3119-3128.
73. Yunis J J, Oken M M, Theologides A, Howe R B, Kaplan M E. Recurrent chromosomal defects are found in most patients with non-Hodakin's lymphoma. Cancer Genet Cytogenet 1984; 13: 17-28.
74. Yana E, Korsmeijer S J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood 1996; 88: 386-401.
75. Richardson M E. Quanguang C, Filippa D A et al. Intermediate to high grade histology of lymphomas carrying t(14;18) is associated with additional non-random chromosome changes. Blood 1987; 70: 444-447.
76. Yunis J J, Oken M M, Kaplan M E, Ensrud K M, Howe R R, Theologides A. Distinctive chromosomal abnormalities in histologie subtypes of non-Hodakin's lymphomas. N Engl J Med 1982; 307: 1231-1236.
77. Horsman D E, Gascoyne R D, Coupland R W, Coldman A J, Adomat S A. Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14;18) in follicular lymphoma. Am J Clin Pathol 1995; 103:472-478.
78. Silverman G A, Ye R D, Pollock K M, Sadler J E, Korsmeyer S J. Use of yeast artificial chromosome clones for mapping and walking within human chromosome segment 18q21.3. Proc Natl Acad Sei USA 1989; 86: 7485-7489.
79. Zelenetz A D, Chu G, Galili N et al. Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis. Blood 1991; 78: 1552-1560.
80. Limpens J, Beelen M, Stad R et al. Detection of the t(14;18) translocation in frozen and formalin-fixed tissue. Diagnostic Molecular Pathology 1993; 2: 99-107.
81. Bertheas M-F, Rimokh R, Berger F et al. Molecular study of a variant translocation t(2;18)(pl I;q21) in a follicular lymphoma. Br J Haematol 1991; 78: 132-134.
82. Aventin A, Mecucci C, Guanyabens C et al. Variant t(2;18) translocation in a Burkitt conversion of follicular lymphoma. Br J Haematol 1990; 74: 367-369.
83. Rimokh R, Gadoux M, Bertheas M-F et al. FVT-1, a novel human transcription unit affected by variant translocation t(2;18)(pll;q2I) of follicular lymphoma. Blood 1993; 81: 136-142.
84. Adachi M, Tefferi A, Greipp P R, Kipps T J, Tsujimoto Y. Preferential linkage of BCL-2 to immunoglobulin light chain gene in chronic lymphocytic leukemia. J Exp Med 1990; 171:559-564.
85. Dyer M J S, Zani V J, Lu W Z et al. BCL2 translocations in leukemias of mature B cells. Blood 1994; 83: 3682-3688.
86. Raghoebier S, Van Krieken J H J M, Kluin-Nelemans J C et al. Oncogene rearrangements in chronic B-cell leukemia. Blood 1991; 77: 1560-1564.
87. Turner G E, Ross F M, Krajewski A S. Detection of t(14;18) in British follicular lymphoma using cytogenetics, Southern blotting and thé polymerase chain reaction. Br J Haematol 1995; 89: 223-225.
88. Ngan B-Y, Nourse J, Cleary M L. Detection of chromosomal translocation t(14;18) within the minor cluster region of bcl-2 by polymerase chain reaction and direct genomic sequencing of the enzymatically amplified DNA in follicular lymphomas. Blood 1989; 73: 1759-1762.
89. Poetsch M, Weber-Matthiesen K, Plendl H J, Grote W, Schlegelberger B. Detection of the t(14;18) chromosomal translocation by interphase cytogenetic with yeast-artificialchromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation. J Clin Oncol 1996; 14: 963-969.
90. Guan X-Y, Horsman D, Zhang H E, Parsa N Z, Meltzer P S, Trent J M. Localization by chromosome microdissection of a recurrent breakpoint region on chromosome 6 in human B-cell lymphoma. Blood 1996; 88: 1418-1422.
91. Bentz M, Werner C A, Döhner H et al. High incidence of chromosomal imbalances and gene amplifications in the classical variant of follicle center lymphoma. Blood 1996; 88: 1437-1444.
92. Manolov G, Maolova Y. Marker band in one chromosome 14 from Burkitt lymphoma. Nature 1972; 237: 33-34.
93. Gelmann E P, Psallidopoulos M C, Papas T S, Dalla-Favera R. Identification of reciprocal translocation sites within the c-myc oncogene and immunoglobulin mu locus in a Burkitt lymphoma. Nature 1983; 306:799-803.
94. Neri A, Barriga F, Knowles D M, Magrath I T, Dalla-Favera R. Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphomas. Proc Natl Acad Sei USA 1988; 85: 2748-2752.
95. Shiramizu B, Barriga F, Neequaye J et al. Patterns of chromosomal breakpoint locations in Burkitt's lymphoma: relevance to geography and Epstein-Barr virus association. Blood 1991; 77: 1516-1526.
96. McKeithan T W. Molecular biology of non-Hodgkin's lymphomas. Semin Oncol 1990; 17: 30-42.
97. Joos S, Haluska F G, Falk M H et al. Mapping chromosomal breakpoints of Burkitt's t(8;14) translocations far upstream of c-myc. Cancer Res 1992; 52: 6547-6552.
98. Henglein B, Synovzik H, Groitl P, Bornkamm G W, HartI P, Lipp M. Three breakpoints of variant t(2;8) translocations in Burkitt's lymphoma cells fall within a region 140 kilobases distal from c-myc. Mol Cell Biol 1989; 9: 2105-2113.
99. Zeidler R, Joos S, Delecluse H-J et al. Breakpoints of Burkitt's lymphoma t(8;22) translocations map within a distance of 300 kb downstream of MYC. Gen Chrom Cane 1994; 9: 282-287.
100. Gutierrez M I, Bhatia K, Barriga F et al. Molecular epidemiology of Burkitt's lymphoma from South America: differences in breakpoint location and Epstein-Barr virus association from tumors in other world regions. Blood 1992; 79: 3261-3266.
101. Van Krieken J H J M, Raffeid M, Raghoebier S, Jaffe E S, Van Ommen G J B, Kluin Ph M. Molecular genetics of gastrointestinal non-Hodgkin's lymphomas: unusual prevalence and pattern of c-myc rearrangements in ageressive lymphomas. Blood 1990; 76: 797-800.
102. Shiramizu B, Magrath I. Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8;14 translocations. Blood 1990; 75: 1848-1852.
103. Müller J R, Janz S, Goedert J J, Potter M, Rabkin C S. Persistence of immunoglobulin heavy chain/C-MYC recombination-positive lymphocyte clones in the blood of human immunodeficiency virus-infected homosexual men. Proc Natl Acad Sei USA 1995; 92: 6577-6581.
104. Ried T, Lengauer C, Cremer T et al. Specific metaphase and interphase detection of the breakpoint region in 8q24 of Burkitt lymphoma cells by triple-color fluorescence in situ hybridization. Gen Chrom Cane 1992; 4: 69-74.
105. Veronese M L, Ohta M, Finan J, Nowell P C, Croce C M. Detection of MYC translocation in lymphoma cells by Fluorescence In Situ Hybridization with Yeast Artificial Chromosomes. Blood 1995; 85: 2132-2138.
106. Kluin P M. Bcl-6 in lymphoma - sorting out a wastebasket? NEnglJMed 1994; 331: 116-118.
107. Limpens J, Stad R, Vos C et al. Lymphoma associated translocation t(14;18) in blood B cells of normal individuals. Blood 1995; 85: 2528-2536.
108. Limpens J, De Jong D, Van Krieken J H J M et al. Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia. Oncogene 1991; 6: 2271-2276.
109. McDonnell T J, Deane N, Platt F M et al. fcc/-2-Immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57: 79-88.
110. Strasser A, Harris A W, Bath M L, Cory S. Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 1990; 348: 331-333.
111. Ye B H, Lista F, Lo Coco F et al. Alterations of a zinc fingerencoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262:747-750.
112. Kerckaert J-P, Deweindt C, Tilly H, Quief S, Lecocq G, Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nature Genet 1993; 5: 66-70.
113. Baron B W, Nucifora G, McCabe N, Espinosa R, III, Le Beau M M, McKeithan T W. Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;ql 1) in B-cell lymphomas. Proc Natl Acad Sei USA 1993; 90: 5262-5266.
114. Miki T, Kawamata N, Hirosawa S, Aoki N. Gene involved in the 3q27 translocation associated with B cell lymphoma, BCL5, encodes a Kriippel-like-Zinc-Finger protein. Blood 199483: 26-32.
115. Baron B W, Billstrand C, Madronero L, McKeithan T W. Hindlll polymorphism in the BCL6 gene. Hum Mol Genet 1993; 2: 1513.
116. Nakamura Y, Miki T, Kawamata N et al. Biallelic DNA rearrangements and deletions within the BCL-6 gene in B-cell non-Hodgkin's lymphoma. Br J Haematol 1995; 90: 404-408.
117. Wlodarska I, Mecucci C, Stul M et al. Fluorescence in situ hybridization identifies new chromosomal changes involving 3q27 in non-Hodgkin's lymphomas with BCL6/LAZ3 rearrangement. Genes Chromosomes Cancer 1995; 14: 1-7.
118. Hebert J, Romana S P, Hillion J, Kerkaert J P, Bastard C, Berger R. Translocation t(3;22)(q27;ql 1) in non-Hodgkin's malignant lymphoma: chromosome painting and molecular studies. Leukemia 1993; 7: 1971-1974.
119. Yunis J J, Mayer M G, Arnesen M A, Aeppli D P, Oken M M, Frizzera G. bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma. N Engl J Med 1989; 320: 1047-1054.
120. Offit K, Koduru P R K, Hollis R et al. 18q21 rearrangement in diffuse large cell lymphoma: incidence and clinical significance. Br J Haematol 1989; 72: 178-183.
121. Raghoebier S, Kramer M H H, Van Krieken J H J M et al. Essential differences in oncogens involvement between primary nodal and extranodal large cell lymphoma. Blood 1991; 78: 2680-2685.
122. Jacobson J O, Wilkes B M, Kwiatkowski D J, Medeiros L J, Aisenberg A C, Harris N L. bcl-2 rearrangements in de novo diffuse large cell lymphoma: association with distinctive clinical features. Cancer 1993; 72: 231-236.
123. Offit K, Lo Coco F, Douie D C. Rearrangement of the BCL-6 gene as a prognostic marker in diffuse large-cell lymphoma. N Engl J Med 1994; 331: 74-80.
124. Hill M E, MacLennan K A, Cunningham D C et al. Prognostic significance of BCL-2 expression and BCL-2 major breakpoint region rearrangement in diffuse large cell Non-Hodgkin's Lymphoma: A British National Lymphoma Investigation study. Blood 1996; 88: 1046-1051.
125. Tang S C, Visser L, Hepperle B, Hanson J, Poppema S. Clinical significance of bcl-2-MBR gene rearrangement and protein expression in diffuse large-cell Non-Hodgkin's Lymphoma: an analysis of 83 cases. J Clin Oncol 1994; 12: 149-154.
126. Hermine O, Haioun C, Lepage E et al. Prognostic significance of bcl-2 protein expression in agsressive Non-Hodgkin's Lymphoma. Blood 1996; 87: 265-272.
127. Kramer M H H, Hermans J, Parker J et al. Clinical significance of bc!2 and p53 protein expression in diffuse large B-cell lymphoma: a population based study. J Clin Oncol 1996; 14:2131-2138.
128. Gribben J G, Neuberg D, Freedman A S et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993; 81: 3449-3457.
129. Gribben J G, Freedman A S, Woo S D et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991; 78: 3275-3280.
130. Price C G A, Meerabux J, Murtagh S et al. The significance of circulating cells carrying t( 14; 18) in long remission from follicular lymphoma. J Clin Oncol 1991; 9: 1527-1532.
131. Finke J, Slanina J, Lange W, Dölken G. Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stace follicular lymphoma. J Clin Oncol 1993; 11: 1668-1673.
132. Ladanyi M, Offit K, Jhanwar S C, Filippa D A, Chaganti R S K. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood 1991; 77: 1057-1063.
133. Scarpa A, Borgato L, Chilosi M et al. Evidence of c-myc gene abnormalities in mediastinal large B-cell lymphoma of young adult age. Blood 1991; 78: 780-788.
134. Yano T, Jaffe E S, Longo D L, Raffeld M. MYC rearrangements in historically progressed follicular lymphomas. Blood 1992; 80: 758-767.
135. Busschots A M, Geerts M-L, Mecucci C, Stul M, Cassiman J-J, Van den Berghe H. A translocation (8; 14) in a cutaneous large B-cell lymphoma. Am J Clin Pathol 1993; 99: 615-621.
136. Lu D, Thompson J D, Gorski G K, Rice N R, Mayer M G, Yunis J J. Alterations at the rel locus in human lymphoma. Oncogene 1991:6:1235-1241.
137. Houldsworth J, Mathew S, Rao P H et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood 1996; 87: 25-29.
138. Joos S, Otano-Joos M I, Ziegler S et al. Primary mediastinal (thymic) B-cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene. Blood 1996; 87: 1571-1578.
139. Kocialkowski S, Pezzella F, Morrison H et al. Mutations in the p53 gene are not limited to classic "hot spots" and are not predictive of p53 protein expression in high grade nonHodgkin's lymphoma. Br J Haematol 1995; 89: 55-60.
140. Ichikawa A, Hotta T, Takagi N et al. Mutations of p53 gene and their relation to disease progression in B-cell lymphoma. Blood 1992:79:2701-2707.
141. Beljaards R C, Kaudewitz P, Berti E et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis: a European multicenter study of 47 patients. Cancer 1993; 71: 2097-2104.
142. Morris S W, Kirstein M N, Valentine M B et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in Non-Hodgkin's lymphoma. Science 1994; 263: 1281-1284.
143. Lamant L, Meggetto F, Al-Saati T et al. High incidence of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma and its lack of detection in Hodgkin's disease. Comparison of cytogenetic analysis, reverse transcriptase-polymerase chain reaction, and P-80 immunostaining. Blood 1996; 87: 284-291.
144. Shiota M, Nakamura S, Ichinohasama R et al. Anaplastic large cell lymphomas expressing the novel chimeric protein pSONPM/ALK: a distinct clinicopathologic entity. Blood 1995; 86: 1954-1960.
145. Wellmann A, Otsuki T, Vogelbruch M, Clark H M, Jaffe E S, Raffeid M. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription polymerase chain reaction in CD30+ anaplastic large cell lymphomas, in other Non-Hodgkin's lymphomas of T-cell type, and in Hodskin's disease. Blood 1995:86:2321-2328.
146. Lopategui J R, Sun L H, Chan J K et al. Low frequency association of the t(2;5)(p23;q35) chromosomal translocation with CD30+ lymphomas from American and Asian patients. A reverse transcriptase-polymerase chain reaction study. Am J Pathol 1995; 146: 323-328.
147. Elmberger P G, Lozano M D, Weisenburger D D, Sanger W, Chan W C. Transcripts of the npm-alk fusion gene in anaplastic large cell lymphoma, Hodgkin's disease, and reactive lymphoid lesions. Blood 1995; 86: 3517-3521.
148. Downing J R, Shurtleff S A, Zielenska M et al. Molecular detection of the (2;5) translocation of non-Hodgkin's lymphoma by reverse transcriptase-polymerase chain reaction. Blood 1995; 85: 3416-3422.
149. Yee H T, Ponzoni M, Merson A et al. Molecular characterization of the t(2;5)(p23;q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease. Blood 1996; 87: 1081-1088.
150. Simonitsch I, Panzer-Gruemayer E R, Ghali D W et al. NPM/ALK gene fusion transcripts identify a distinct subgroup of null type Ki-1 positive anaplastic large cell lymphomas. Br J Haematol 1996; 92: 866-871.
151. DeCoteau J F, Butmarc J R, Kinney M C, Kadin M E. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87: 3437-3441.
152. Beylot-Barry M, Lamant L, Vergier B et al. Detection of t(2;5)(p23;35) translocation by reverse transcriptase polymerase chain reaction and in situ hybridization in CD30-positive primary cutaneous lymphoma and lymphomatoid papulosis. Am J Clin Pathol 1996; 149:483-492.
153. Orscheschek K, Merz H, Hell J, Binder T, Bartels H, Feller A C. Large-cell anaplastic lymphoma-specific translocation t(2;5)(p23; q35) in Hodgkin's disease: indication of a common pathogenesis? [see comments]. Lancet 1995; 345: 87-90.
154. Weiss L M, Lopategui J R, Sun L H, Kamel O W, Koo C H, Glackin C. Absence of the t(2;5) in Hodgkin's disease. Blood 1995; 85: 2845-2847.
155. Dirks W G, Zaborski M, Jager K et al. The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines. Leukemia 1996; 10: 142-149.